Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.clinthera.2009.05.006

Indexing Status
Subject indexing assigned by NLM

MeSH
Administration, Oral; Adult; Aged; Anti-Inflammatory Agents /administration & dosage /economics /therapeutic use; Canada; Chronic Disease; Cost-Benefit Analysis /methods /statistics & numerical data; Decision Support Techniques; Humans; Immunoglobulins, Intravenous /administration & dosage /economics /therapeutic use; Middle Aged; Models, Economic; Prednisone /administration & dosage /economics /therapeutic use; Purpura, Thrombocytopenic /drug therapy /economics; Quality-Adjusted Life Years; Sensitivity and Specificity; Treatment Outcome

AccessionNumber
22009102505

Date bibliographic record published
03/02/2010